Proteome CK1D inhibitors improve cognitive function in in-vivo Alzheimer’s disease study

Study results established the efficacy of the company’s compounds for CK1D and provided important in-vivo proof of principle.

Proteome Sciences chief operating officer Dr. Ian Pike said the results additionally validate PS Biomarker Services’ proteomic approach in the discovery of new drug targets in challenging diseases.

"By diligently following the tau hypothesis of Alzheimer’s disease we have been able to develop exciting new therapeutic strategies that are increasingly recognised by the scientific community as important components of the fight to halt Alzheimer’s disease progression," Pike added.

Previous in-vitro study demonstrated that CK1D inhibitors block tau phosphorylation in cell lines.

Next phase to commence and complete a comprehensive assessment of biological indicators and drug levels in a range of tissues is anticipated to begin in January 2013.

Proteome Sciences CEO Christopher Pearce said, "In light of UK Government’s recent commitment to fully fund NHS access to novel treatments for AD we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers."